Patents by Inventor KATHLEEN A. SLUKA

KATHLEEN A. SLUKA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MALATE TO DETECT AND AS A TARGET FOR FIBROMYALGIA
    Publication number: 20220065846
    Abstract: Methods of detecting malate, and monitoring fibromyalgia, are provided.
    Type: Application
    Filed: September 1, 2021
    Publication date: March 3, 2022
    Inventor: Kathleen A. Sluka
  • Use of RNAi technology to inhibit ASIC3
    Patent number: 8518902
    Abstract: In vitro studies using cells transfected with acid-sensing ion channel 3 (ASIC3) or acid-sensing ion channel 1 (ASIC1) cDNA, demonstrated that the miRNAs against mouse ASIC3 (miR844 and miR847) selectively inhibit mouse ASIC3, but not ASIC1 as detected by protein expression and responses to pH. When the RNAi agents, miR844 or miR847, were used in vivo, delivered into the muscle of mice using a replication-defective herpes simplex viral (HSV-1) vector, primary and secondary hyperalgesia were reduced after carrageenan-induced muscle inflammation. Accordingly, the present invention provides RNAi agents that target ASIC3, methods of preparing such RNAi agents, and methods of using them to modulate in a cell the level of ASIC3 or activity of an ASIC including at least one ASIC3. Modulation of ASIC3 activity or levels can be used for different purposes such as treating pain associated with the expression of ASIC3 and the like.
    Type: Grant
    Filed: January 31, 2011
    Date of Patent: August 27, 2013
    Assignee: University of Iowa Research Foundation
    Inventors: Kathleen A. Sluka, Roxanne Y. Walder
  • USE OF RNAi TECHNOLOGY TO INHIBIT ASIC3
    Publication number: 20110237645
    Abstract: In vitro studies using cells transfected with acid-sensing ion channel 3 (ASIC3) or acid-sensing ion channel 1 (ASIC1) cDNA, demonstrated that the miRNAs against mouse ASIC3 (miR844 and miR847) selectively inhibit mouse ASIC3, but not ASIC1 as detected by protein expression and responses to pH. When the RNAi agents, miR844 or miR847, were used in vivo, delivered into the muscle of mice using a replication-defective herpes simplex viral (HSV-1) vector, primary and secondary hyperalgesia were reduced after carrageenan-induced muscle inflammation. Accordingly, the present invention provides RNAi agents that target ASIC3, methods of preparing such RNAi agents, and methods of using them to modulate in a cell the level of ASIC3 or activity of an ASIC including at least one ASIC3. Modulation of ASIC3 activity or levels can be used for different purposes such as treating pain associated with the expression of ASIC3 and the like.
    Type: Application
    Filed: January 31, 2011
    Publication date: September 29, 2011
    Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATION
    Inventors: KATHLEEN A. SLUKA, ROXANNE Y. WALDER